Table 5. Distribution of polymorphisms in both populations.
| Healthy Donors | Patients | |||||
|---|---|---|---|---|---|---|
| AfricansNo. (%) | CaucasiansNo. (%) | P | AfricansNo. (%) | CaucasiansNo. (%) | P | |
| A1012G | ||||||
| TT+CT | 49 (98) | 45 (90) | 18 (100) | 31 (88.6) | ||
| CC | 1 (2) | 5 (10) | ns | 0 | 4 (11.4) | ns |
| TT | 45 (90) | 20 (40) | 18 (100) | 12 (34.3) | ||
| CT+CC | 5 (10) | 30 (60) | < 0.0001 | 0 | 23 (65.7) | < 0.0001 |
| Cdx2 | ||||||
| AA+GA | 48 (96) | 24 (48) | 18 (100) | 15 (42.9) | ||
| GG | 2 (4) | 26 (52) | < 0.0001 | 0 | 20 (57.1) | < 0.0001 |
| AA | 39 (78) | 4 (8) | 18 (100) | 4 (11.4) | ||
| GA+GG | 11 (22) | 46 (92) | < 0.0001 | 0 | 31 (88.6) | < 0.0001 |
| Fok1 | ||||||
| TT+CT | 15 (30) | 27 (54) | 11 (61.1) | 21 (60) | ||
| CC | 35 (70) | 23 (46) | 0.00253 | 7 (38.9) | 14 (40) | ns |
| TT | 1 (2) | 8 (16) | 3 (16.7) | 5 (14.3) | ||
| CC+CT | 49 (98) | 42 (84) | 0.03 | 15 (83.3) | 30 (85.7) | ns |
| rs4588 | ||||||
| AA+CA | 19 (38) | 20 (40) | 7 (38.6) | 17 (48.6) | ||
| CC | 31 (62) | 30 (60) | ns | 11 (61.1) | 18 (51.4) | ns |
| AA | 0 (0) | 1 (2) | 0 | 2 (5.7) | ||
| CA+CC | 50 (100) | 49 (98) | ns | 18 (100) | 33 (94.3) | ns |
| rs7041 | ||||||
| GG+TG | 8 (16) | 41 (82) | 3 (16.7) | 28 (80) | ||
| TT | 42 (84) | 9 (18) | < 0.0001 | 15 (83.3) | 7 (20) | < 0.0001 |
| GG | 0 (0) | 16 (32) | 0 (0) | 13 (37.1) | ||
| TG+TT | 50 (100) | 34 (68) | 0.002 | 18 (100) | 22 (66.0) | 0.02 |
ns = not significant.
Comparison between cases and controls within each population.
The statistically significant comparisons in the African population were: Cdx2 AA vs. GA+GG (P=0.02); Fok1: TT+CTA vs. CC (P=0.02).
No statistically significant comparisons appeared within the Caucasian population.